<DOC>
	<DOC>NCT02063100</DOC>
	<brief_summary>-Evaluate the efficacy and safety of Shenyankangfu Tablets to control the proteinuria of patients with primary glomerulonephritis compare with Losartan potassium.</brief_summary>
	<brief_title>Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis</brief_title>
	<detailed_description />
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Inclusion Diagnosed with primary glomerulonephritis Aged from 18 to 70 years，male or female Blood pressure can be controlled ≤140/90mmHg GFR≥45ml/min/1.73㎡ 0.5g≤24 hours proteinuria≤3.0g Traditional Chinese medicine syndrome conform QiYin Deficiency Obtain the agreement of patients or their guardians, and signed informed consent file secondary nephropathy Take the glucocorticoid,immunosuppressants and Tripterygium drug in the last 12 months Take other Chinese patent medicine and decoction which can reduce proteinuria in the last 2 weeks Take reninangiotensin system blockers in last 4 weeks Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life Pregnant or lactating women Allergic predisposition or known to be allergic to the drug composition Blood presser ＜90/60mmHg With unilateral or bilateral renal artery stenosis With mental disorders and poor compliance Be suspected or confirmed with alcohol, drug abuse history Be participating in another clinical study at the same period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Glomerulonephritis</keyword>
	<keyword>proteinuria</keyword>
	<keyword>shenyankangfu tablets</keyword>
	<keyword>Losartan Potassium</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>